AU2019349424B2 - 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof - Google Patents

2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof Download PDF

Info

Publication number
AU2019349424B2
AU2019349424B2 AU2019349424A AU2019349424A AU2019349424B2 AU 2019349424 B2 AU2019349424 B2 AU 2019349424B2 AU 2019349424 A AU2019349424 A AU 2019349424A AU 2019349424 A AU2019349424 A AU 2019349424A AU 2019349424 B2 AU2019349424 B2 AU 2019349424B2
Authority
AU
Australia
Prior art keywords
compound
effective amount
subject
administering
aza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2019349424A
Other languages
English (en)
Other versions
AU2019349424A1 (en
Inventor
Omar Diego LOPEZ
Joel Morris
Donn G. Wishka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2019349424A1 publication Critical patent/AU2019349424A1/en
Application granted granted Critical
Publication of AU2019349424B2 publication Critical patent/AU2019349424B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2019349424A 2018-09-25 2019-09-23 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof Ceased AU2019349424B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736246P 2018-09-25 2018-09-25
US62/736,246 2018-09-25
PCT/US2019/052410 WO2020068657A1 (en) 2018-09-25 2019-09-23 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof

Publications (2)

Publication Number Publication Date
AU2019349424A1 AU2019349424A1 (en) 2021-03-18
AU2019349424B2 true AU2019349424B2 (en) 2024-04-04

Family

ID=68136598

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019349424A Ceased AU2019349424B2 (en) 2018-09-25 2019-09-23 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof

Country Status (7)

Country Link
US (2) US20220033387A1 (https=)
EP (1) EP3856754A1 (https=)
JP (1) JP7520822B2 (https=)
CN (1) CN112888698A (https=)
AU (1) AU2019349424B2 (https=)
CA (1) CA3110224A1 (https=)
WO (1) WO2020068657A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7520822B2 (ja) * 2018-09-25 2024-07-23 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－ハロゲン化－４’－チオ－２’－デオキシ－５－アザシチジンアナログおよびその使用
EP4138843A4 (en) * 2020-04-23 2024-07-10 Southern Research Institute COMPOSITION FOR THE TREATMENT OF BLOOD CANCER USING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND USES THEREOF
CN114644668B (zh) * 2020-12-18 2026-04-14 鲁南制药集团股份有限公司 一种合成地西他滨的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
DK0841344T3 (da) * 1996-04-09 2002-12-23 Yamasa Corp 1-(2-Desoxy-2-fluor-4-thio-Beta-D-arabinofuranosyl)cytosiner
ES2565929T3 (es) * 2004-10-25 2016-04-07 Dekk-Tec, Inc. Sales de mostaza de isofosforamida y análogos de las mismas como agentes antitumorales
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
JP5616968B2 (ja) 2009-12-18 2014-10-29 株式会社リブラメディシーナ 置換された１−Ｏ−アシル−２−デオキシ−２−フルオロ−４−チオ−β−Ｄ−アラビノフラノース類の製造方法
AU2013241341B2 (en) 2012-03-28 2016-09-08 Fujifilm Corporation Salt of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine
DK2883866T3 (da) 2012-08-13 2019-05-13 Fujifilm Corp MELLEMPRODUKT TIL SYNTESE AF 1-(2-DEOXY-2-FLUOR-4-THIO-beta-D- ARABINOFURANOSYL)CYTOSIN, MELLEMPRODUKT TIL SYNTESE AF THIONUKLEOSID OG FREMGANGSMÅDER TIL FREMSTILLING AF DISSE MELLEMPRODUKTER
CN103626765B (zh) * 2012-08-27 2016-08-10 广东东阳光药业有限公司 取代的氮杂吲哚化合物及其盐、组合物和用途
WO2015125781A1 (ja) 2014-02-18 2015-08-27 富士フイルム株式会社 チオラン骨格型糖化合物の製造方法およびチオラン骨格型糖化合物
JP6450356B2 (ja) 2016-02-29 2019-01-09 富士フイルム株式会社 液状医薬製剤
JP7425734B2 (ja) 2018-02-01 2024-01-31 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－デオキシヌクレオシドを製造するための立体選択的合成およびプロセス
JP7520822B2 (ja) * 2018-09-25 2024-07-23 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－ハロゲン化－４’－チオ－２’－デオキシ－５－アザシチジンアナログおよびその使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOZHOK T S ET AL: "Synthesis, Hydrolytic Stability, and Antileukemic Activity of Azacytidine Nucleoside Analogs", PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 49, no. 12, 4 April 2016, pages 804 - 809, DOI: 10.1007/S11094-016-1375-4 *
JAIDEEP V. THOTTASSERY ET AL: "Novel DNA methyltransferase-1...5-aza-4'-thio-2'-deoxycytidine", CANCER CHEMOTHERAPY AND PHARMACOLOGY., vol. 74, no. 2, 8 June 2014, pages 291 - 302, DOI: 10.1007/s00280-014-2503-z *
KAMAL N. TIWARI ET AL: "Synthesis and Anti-cancer Activity of Some Novel 5-Azacytosine Nucleosides", NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS., vol. 22, no. 12, 31 December 2003 (2003-12-31), pages 2161 - 2170, DOI: 10.1081/NCN-120026872 *
RICHARD DAIFUKU ET AL: "5-aza-2',2'-Difluoro Deoxycytidine (NUC013): A Novel Nucleoside...for the Treatment of Cancer", PHARMACEUTICALS, vol. 10, no. 3, 20 July 2017, pages 65, DOI: 10.3390/ph10030065 *

Also Published As

Publication number Publication date
EP3856754A1 (en) 2021-08-04
JP2022502378A (ja) 2022-01-11
US20220033387A1 (en) 2022-02-03
CA3110224A1 (en) 2020-04-02
US11254662B2 (en) 2022-02-22
CN112888698A (zh) 2021-06-01
JP7520822B2 (ja) 2024-07-23
WO2020068657A8 (en) 2021-03-18
AU2019349424A1 (en) 2021-03-18
US20210292310A1 (en) 2021-09-23
WO2020068657A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
JP6805220B2 (ja) 治療上活性な化合物およびそれらの使用方法
CN109152933B (zh) 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
ES2402791T3 (es) Forma cristalina de la sal diclorhidrato de ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo
US11254662B2 (en) 2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof
CA3149594A1 (en) Substituted pyridopyrimidinonyl compounds useful as t cell activators
US20140073643A1 (en) Treatment of jak2-mediated conditions
US8212033B2 (en) Use of substituted quinazoline compounds in treating angiogenesis-related diseases
JPH05506854A (ja) 局部活性眼用チアジアゾールスルホンアミドカルボニックアンヒドラーゼ抑制剤
ES2987563T3 (es) Moduladores del receptor de glucocorticoides ciclohexenilo pirimidina
US20100266674A1 (en) L-oddc prodrugs for cancer
EA019289B1 (ru) Производные аминопиридина, аминопиримидина и амино-1,3,5-триазина
JP6615207B2 (ja) 複素環式化合物及びその使用
EA023104B1 (ru) Аналоги эпоксиэйкозатриеновой кислоты и способы их получения и использования
TW201639824A (zh) 新穎水溶性前藥
EP0373663B1 (en) Castanospermine esters in the inhibition of tumor metastasis
JP7679129B2 (ja) コルジセピンの誘導体化による抗腫瘍効果を有する化合物
JP2020518649A5 (https=)
RU2195451C2 (ru) Цианогуанидины, способы их получения и фармацевтический препарат на их основе
US5180717A (en) Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
JP6271091B2 (ja) 新規シチジン誘導体二量体およびその応用
WO2010080170A1 (en) Combination therapies for neoplastic disorders
JP2010520236A (ja) リソフィリンアナログとその使用法
US6251898B1 (en) Medical use of fluorenone derivatives for treating and preventing brain and spinal injury
CN115260107B (zh) 一种抗肿瘤药物前药、药物组合物及在肿瘤靶向治疗领域的应用
JPS6337787B2 (https=)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired